Neoadjuvant pembrolizumab plus chemotherapy in older patients with early-stage triple-negative breast cancer: real-world insights from neo-real/GBECAM-0123

Abstract The KEYNOTE-522 regimen is the standard of care for stage II–III triple-negative breast cancer (TNBC). However, older patients were underrepresented in the pivotal trial. We evaluated the effectiveness and safety of this regimen in patients aged ≥65 years enrolled in the Neo-Real/GBECAM-012...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Mariana Carvalho Gouveia, Romualdo Barroso-Sousa, Laura Lapuchesky, Laura Testa, Monique Celeste Tavares, Flávia Cavalcanti Balint, Carlos Henrique dos Anjos, Débora de Melo Gagliato, Mayana Lopes de Brito, Giuliana Colucci, Daniele Assad-Suzuki, Daniela Dornelles Rosa, Noele de Jesus Barros Gomes, Natalia Cristina Cardoso Nunes, Isadora Martins de Sousa, Matheus de Oliveira Andrade, Fernanda Madasi, Jose Bines, Mariana Savignano, Rafael Dal Ponte Ferreira, Candice Lima Santos, Maira Tavares, Mariana Ribeiro Monteiro, Zenaide Silva de Souza, Ana Maria Ulbricht Gomes, Bruna M. Zucchetti, Anezka Ferrari, Maria Marcela Fernandes Monteiro, Poliana Albuquerque Signorini, Solange Sanches, Paulo M. Hoff, Claudio Paletta, Maria del Pilar Estevez-Diz, Renata Colombo Bonadio
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Nature Portfolio 2026-03-01
סדרה:	npj Breast Cancer
גישה מקוונת:	https://doi.org/10.1038/s41523-026-00919-y
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!